Week in review: Everest sells trodelvy rights back to Gilead for $455 million
Everest Medicines returned rights for Trodelvy to Immunomedics. Nanchang Jemincare out-licensed global rights for its prostate cancer candidate to Genentech in a $650 million deal.
New Jersey United States Bennu Biotherapeutics Equecabtagene Autoleucel Life Science Park Innovation Fund Gilead Sciences
Source: seekingalpha.com